BioCentury
ARTICLE | Clinical News

Xanelim anti-CD11a: Phase III

March 4, 2002 8:00 AM UTC

Pooled data from 1095 patients in 2 Phase III trials showed that 29% and 28% of patients treated for 12 weeks with 1 mg/kg and 2 mg/kg of Xanelim, respectively, had a 75% PASI improvement compared to ...